Use of a vaniloid receptor agonist together with a glycosaminoglycan or a proteoglycan for the manufacture of a drug for the treatment of joint pain and procedure for the application of this drug

摘要

Use of a vaniloid receptor agonist together with a glycosaminoglycan or proteoglycan for the manufacture of a drug for the treatment of pain, in which A) the vaniloid receptor agonist is resiniferatoxin (RTX) as well as its salts; and B) glycosaminoglycan or proteoglycan are chosen from the following group: hyaluronic acid, as well as substrates; characterized in that (i) in the case of an intraarticular injection of 9 ml of a solution of 500 nM of resiniferatoxin and 1% of hyaluronic acid, not simultaneously injecting 0.03 mg of vincristine; (ii) in the case of an intraarticular injection of 0.9 ml of a solution of 500 nM of resiniferatoxin and 1% of hyaluronic acid, 0.03 mg of vincristine is injected simultaneously; and (iii) in the case of a 9 ml intra-articular injection of a solution of 500 nM of resiniferatoxin and 1% hyaluronic acid, 0.5 mg / m2 of vincristine is administered simultaneously intravenously for 24 hours.